Venlo, the Netherlands, June 05, 2024 (GLOBE NEWSWIRE) -- QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the launch of its new digital PCR (dPCR) Custom Assay Design Tool for copy ...

VENLO, the Netherlands--(BUSINESS WIRE)-- QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the expansion of its cell and gene therapy (CGT) portfolio with an enhanced digital PCR ...

Expands range of applications for successful QIAcuity digital PCR platforms, now entering the clinical space across North America and the EU // Provides absolute quantitation, essential for precise ...

At its J.P. Morgan Healthcare Conference 2026 presentation, Qiagen NV alluded to positive full-year results for 2025 and ...

QIAGEN N.V. QGEN recently launched its QIAcuityDx Digital PCR System, whose instrument and accessories are Food and Drug Administration (“FDA”) 510(k) approved and In Vitro Diagnostic Regulation ...

Venlo, the Netherlands, June 11, 2024 (GLOBE NEWSWIRE) -- QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the launch of 35 new wet-lab tested digital PCR Microbial DNA Detection ...

VENLO, Netherlands--(BUSINESS WIRE)--QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced a significant increase in the powerful capabilities of its QIAcuity Digital PCR (dPCR) system ...

Venlo, the Netherlands, Sept. 18, 2024 (GLOBE NEWSWIRE) -- QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced an important milestone with the launch of 100 new assays for its digital ...

Venlo, the Netherlands, Nov. 27, 2024 (GLOBE NEWSWIRE) -- QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the launch of two new tools for designing and ordering custom solutions ...

The new partnership combines QIAGEN’s QIAcuityDx digital PCR platform to advance sensitive, cost-effective oncology diagnostics with GENCURIX’s expertise in multiplex assay development. The aim is to ...